Pro-inflammatory skin microbiome bacteria

Pro-inflammatory bacterial strains in the skin microbiome, such as specific phylotypes of Cutibacterium acnes and Staphylococcus aureus, are key drivers of cutaneous inflammation and barrier dysfunction [1][2]. These organisms act as pathobionts, transitioning from commensal to pathogenic states under conditions of dysbiosis, where they trigger innate immune pathways via Toll-like receptors (TLRs) [3][4]. Their biological activities include the production of virulence factors like lipases, proteases, and toxins that degrade the skin barrier and induce the release of pro-inflammatory cytokines such as IL-1β and IL-17 [2][5]. Therapeutic intervention often involves broad-spectrum antibiotics, though modern strategies are shifting toward precision microbiome modulation, including phage therapy and prebiotics, to selectively reduce these strains while preserving beneficial commensals [1][6]. Targeting these bacteria is essential for managing chronic conditions like acne vulgaris, atopic dermatitis, and psoriasis [2][4].

Other names

Pathogenic skin bacteriaSkin pathobiontsDysbiotic skin microbiotaPro-inflammatory skin strains

Drugs targeting these bacteria typically act through direct bactericidal or bacteriostatic effects, such as inhibiting protein synthesis, disrupting cell wall integrity, or generating reactive oxygen species [1][2]. Newer approaches focus on selective inhibition or competitive exclusion to restore microbial balance without broad-spectrum depletion [4][6].